# Bioequivalence of Telmisartan / HCTZ Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

> **NCT02262624** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Telmisartan
- **DRUG:** Hydrochlorthiazide (HCTZ)
- **DRUG:** Telmisartan/HCTZ fixed combination

## Key facts

- **NCT ID:** NCT02262624
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2005-02
- **Final completion:** —
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2014-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02262624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02262624, "Bioequivalence of Telmisartan / HCTZ Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02262624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*